NeoGenomics surges 28% on Q3 beat as clinical services revenue grows

Nov. 08, 2022 11:57 AM ETNeoGenomics, Inc. (NEO)By: Ravikash, SA News Editor

glowing graph 2

Jonathan Kitchen

  • NeoGenomics (NASDAQ:NEO) stock rose ~28% on Tuesday after Q3 results beat estimates.
  • Adjusted net loss widened to -$17.9M, compared to -$9.77M in Q3 2021.
  • Total net revenue grew +6.13% Y/Y to $128.78M.
  • Clinical Services revenue increased +3.85% Y/Y to $106.16M. The company said Clinical

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.